|
|
CAF-01 |
|
Vaxjo ID |
151 |
|
Vaccine Adjuvant Name |
CAF-01 |
|
Adjuvant VO ID |
VO_0005483
|
|
Description |
A vaccine adjuvant is a gadoteridol-loaded cationic adjuvant formulation 01 that induced a Th1/Th17 type of immune response |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
Denmark |
|
Components |
cationic liposomes based on the surfactant dimethyldioctadecylammonium (DDA) bromide and the glycolipid trehalose-6,6’-dibehenate (TDB) |
|
Preparation |
liposomes prepared using thin film method |
|
Function |
antigen and activates DCs, induces both humoral and cell-mediated memory immune response |
| References |
Kloverpris et al., 2009: Kloverpris H, Karlsson I, Bonde J, Thorn M, Vinner L, Pedersen AE, Hentze JL, Andresen BS, Svane IM, Gerstoft J, Kronborg G, Fomsgaard A. Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. AIDS (London, England). 2009; 23(11); 1329-1340. [PubMed: 19528789].
Thakur et al., 2020: Thakur A, Pinto FE, Hansen HS, Andersen P, Christensen D, Janfelt C, Foged C. Intrapulmonary (i.pulmon.) Pull Immunization With the Tuberculosis Subunit Vaccine Candidate H56/CAF01 After Intramuscular (i.m.) Priming Elicits a Distinct Innate Myeloid Response and Activation of Antigen-Presenting Cells Than i.m. or i.pulmon. Prime Immunization Alone. Frontiers in immunology. 2020; 11; 803. [PubMed: 32457748].
|
|
